|D029424||Pulmonary Disease, Chronic Obstructive NIH||0.38|
|D008173||Lung Diseases, Obstructive NIH||0.35|
|D008171||Lung Diseases, NIH||0.21|
There is one clinical trial.
The purpose of the study is to investigate the addition of high frequency chest wall oscillation (HFCWO) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-COVID patients with COPD and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from COVID-19.
Description: Change in forced expiratory volume in one second (FEV1) as compared to baseline, measured by home spirometer.Measure: Change in forced expiratory volume in one second (FEV1) Time: Baseline and up to 90 Days
Description: Changes in oxygen saturation from baseline as measured by pulse oximeter. Normal oxygen range is 95 to 100 percent and low oxygen range is under 90 percent.Measure: Change in Oxygen Saturation level Time: Baseline and up to 90 Days
Description: Changes in basal temperature as measured by digital thermometer. Fever is indicated at 100.4 F (38 C) or higher.Measure: Change in Presence of Fever Time: Baseline and up to 90 Days
Description: CAP Symptom Questionnaire records how much the patient rated the bothersomeness of the symptom. Each item is scored as "0" (Patient did not have this symptom), "1" (Not at All) to "5" (Extremely). Full range scale from 0 to 90, higher score indicating patient experiencing more frequent or more severe symptoms.Measure: Change in Presence of pneumonia symptoms via Community Acquired Pneumonia (CAP) Symptom Questionnaire Time: Baseline and up to 90 Days
Description: The QOL-B is a disease-specific questionnaire that measures symptoms, functioning, and health-related quality of life relevant to patients with bronchiectasis. Scores are generated from 37 items that fall on 8 domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms. All subscales and the full range scale are standardized to score from 0 to 100, with higher scores indicating better enjoyment and satisfaction with specific life domains.Measure: Change in Quality of life via Quality of Life Questionnaire-Respiratory (QOL-B) Time: Baseline and up to 90 Days
Description: The PHQ-8 is the depression module, which scores each of the eight DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-24, with higher score indicating more severe symptoms.Measure: Change in Mental health screening via Personal Health Questionnaire Depression Scale (PHQ-8) Time: Baseline and up to 90 Days
Description: The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire that asks user to rank how often they have been bothered by seven problems over the past two weeks from "0" (not at all) to "3" (nearly every day). Full scale from 0-21, with higher score indicating more symptoms.Measure: Change in Mental health screening via General Anxiety Disorder-7 (GAD-7) Time: Baseline and up to 90 Days
Description: Eight questions that are specific to recent literature describing patients' experiences of symptoms during COVID. They are rated on a frequency scale from "never" to "always," using a 1-4 point scale. Full scale range from 8 to 32, with higher scores indicating more frequent symptoms.Measure: Change in COVID Symptom Checklist Time: Baseline and up to 90 Days
Description: Amount of time used per week in minutesMeasure: AffloVest Usage Time: 90 Days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports